HRT Financial’s Biogen BIIB Stock Holding History

HRT Financial’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,000	Closed	-$1.41M	–	3208
2021 Q3	$1.41M	Buy	+5,000	New	+$1.64M	0.01%	985
2020 Q1	–	Sell	-1,400	Closed	-$415K	–	794
2019 Q4	$415K	Sell	1,400 -5,700	-80%	-$1.58M	0.02%	599
2019 Q3	$1.65M	Buy	+7,100	New	+$1.65M	0.08%	214

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HRT Financial's BIIB Position: Q1 2026 in Review

HRT Financial sold out of Biogen (BIIB) in Q1 2026, closing a stake of 384,265 shares — an estimated $67.6M sold.

HRT Financial first reported a position in BIIB in Q1 2015 and held it in 20 quarters. The position peaked at $67.6M in Q4 2025. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

HRT Financial reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 384,265 Biogen shares in Q1 2026, an estimated $67.6M.
HRT Financial first reported a position in Biogen in Q1 2015 and held it in 20 quarters.
HRT Financial's Biogen position peaked at $67.6M in Q4 2025.
1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.